High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

Figure 2 Combinatorial therapy with high-frequency irreversible electroporation, BMS-1, and R848 prolongs survival and inhibits tumor growth in hepatoma 22 subcutaneous tumor-bearing mice. A: Schematic of the hepatoma 22 subcutaneous tumor model and experimental treatment timeline; B: Kaplan-Meier survival curves across the different treatment groups (n = 8); C: Tumor growth kinetics presented as dynamic volume curves over the observation period (n = 8); D: Comparison of subcutaneous tumor volumes measured on day 21 post-treatment (n = 8). ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001. i.p.: Intraperitoneal; i.t.: Intratumoral; H-FIRE: High-frequency irreversible electroporation; H22: Hepatoma 22.